[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjSlc3uH8xh93amsIOMiZ-BZ34XMrzBfRiPLxlZ5K82U":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Minneapolis Veterans Affairs Medical Center",[4],40,false,4,6,6910,25,[13,15,18,20,23,25,27,29],{"name":14,"count":8},"Traumatic Brain Injury",{"name":16,"count":17},"Chronic Pain",3,{"name":19,"count":17},"Type 2 Diabetes",{"name":21,"count":22},"Arthritis",2,{"name":24,"count":22},"Diabetes Mellitus",{"name":26,"count":22},"Alcoholism",{"name":28,"count":22},"Metabolic Syndrome",{"name":30,"count":22},"Osteoarthritis, Knee",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06228391","Ketamine Treatment for PTSD and MDD in TBI","2026-12","IV ketamine",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07332299","Remote Stimulation and Training to Advance Recovery From TBI in Seniors","2027-09","Active tDCS and Cognitive Training Intervention",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,76,94,116,134,160,185,210,237,255,290,316,342,369,392,418,436,463],{"intervention":36,"totalTrials":51,"cells":52},1,{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":70,"PHASE4":72,"NA":74},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":51,"soonestReadout":35},[60],{"nctId":33,"briefTitle":34,"status":61,"phases":62,"primaryCompletion":35,"completion":63,"start":64,"enrollment":6,"conditions":65,"interventions":68},"NOT_YET_RECRUITING",[45],"2027-03","2024-03",[66,67,14],"PTSD, Post Traumatic Stress Disorder","Major Depressive Disorder",[36,69],"Midazolam",{"trials":71,"activeCount":55},[],{"trials":73,"activeCount":55},[],{"trials":75,"activeCount":55},[],{"intervention":69,"totalTrials":51,"cells":77},{"EARLY_PHASE1":78,"PHASE1":80,"PHASE2":82,"PHASE3":88,"PHASE4":90,"NA":92},{"trials":79,"activeCount":55},[],{"trials":81,"activeCount":55},[],{"trials":83,"activeCount":51,"soonestReadout":35},[84],{"nctId":33,"briefTitle":34,"status":61,"phases":85,"primaryCompletion":35,"completion":63,"start":64,"enrollment":6,"conditions":86,"interventions":87},[45],[66,67,14],[36,69],{"trials":89,"activeCount":55},[],{"trials":91,"activeCount":55},[],{"trials":93,"activeCount":55},[],{"intervention":41,"totalTrials":51,"cells":95},{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":106},{"trials":97,"activeCount":55},[],{"trials":99,"activeCount":55},[],{"trials":101,"activeCount":55},[],{"trials":103,"activeCount":55},[],{"trials":105,"activeCount":55},[],{"trials":107,"activeCount":51,"soonestReadout":40},[108],{"nctId":38,"briefTitle":39,"status":109,"phases":110,"primaryCompletion":40,"completion":40,"start":111,"enrollment":6,"conditions":112,"interventions":114},"RECRUITING",[48],"2026-01-15",[14,113],"Aging Related Cognitive Decline",[41,115],"Sham tDCS and Cognitive Training Intervention",{"intervention":115,"totalTrials":51,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":119,"activeCount":55},[],{"trials":121,"activeCount":55},[],{"trials":123,"activeCount":55},[],{"trials":125,"activeCount":55},[],{"trials":127,"activeCount":55},[],{"trials":129,"activeCount":51,"soonestReadout":40},[130],{"nctId":38,"briefTitle":39,"status":109,"phases":131,"primaryCompletion":40,"completion":40,"start":111,"enrollment":6,"conditions":132,"interventions":133},[48],[14,113],[41,115],{"intervention":135,"totalTrials":51,"cells":136},"nicotine replacement patch",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":158},{"trials":138,"activeCount":55},[],{"trials":140,"activeCount":55},[],{"trials":142,"activeCount":55},[],{"trials":144,"activeCount":55},[],{"trials":146,"activeCount":55},[147],{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT00000444","Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)","COMPLETED",[47],"2004-01","1997-09",500,[26,156],"Smoking",[135],{"trials":159,"activeCount":55},[],{"intervention":161,"totalTrials":51,"cells":162},"Gabapentin",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":181,"NA":183},{"trials":164,"activeCount":55},[],{"trials":166,"activeCount":55},[],{"trials":168,"activeCount":55},[],{"trials":170,"activeCount":55},[171],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"completion":176,"start":177,"enrollment":6,"conditions":178,"interventions":180},"NCT00533455","Gabapentin for the Treatment of Neuroleptic-Induced Tremor","TERMINATED",[46],"2007-08","2004-03",[179],"Neuroleptic-Induced Tremor",[161],{"trials":182,"activeCount":55},[],{"trials":184,"activeCount":55},[],{"intervention":186,"totalTrials":51,"cells":187},"intra-articular botulinum toxin type a",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":206,"NA":208},{"trials":189,"activeCount":55},[],{"trials":191,"activeCount":55},[],{"trials":193,"activeCount":55},[],{"trials":195,"activeCount":55},[196],{"nctId":197,"briefTitle":198,"status":199,"phases":200,"completion":201,"start":202,"enrollment":6,"conditions":203,"interventions":205},"NCT00211718","Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain","UNKNOWN",[46],"2007-06","2004-07",[21,204],"Shoulder Pain",[186],{"trials":207,"activeCount":55},[],{"trials":209,"activeCount":55},[],{"intervention":211,"totalTrials":51,"cells":212},"consensus interferon (Interferon Alfacon-1) and ribavirin",{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":233,"NA":235},{"trials":214,"activeCount":55},[],{"trials":216,"activeCount":55},[],{"trials":218,"activeCount":55},[],{"trials":220,"activeCount":55},[221],{"nctId":222,"briefTitle":223,"status":150,"phases":224,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT00211692","Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial",[46],"2008-07","2009-09","2005-07",64,[230],"Chronic Hepatitis C",[211,232],"Consensus Interferon alfa (CIFN) and ribavirin",{"trials":234,"activeCount":55},[],{"trials":236,"activeCount":55},[],{"intervention":232,"totalTrials":51,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":251,"NA":253},{"trials":240,"activeCount":55},[],{"trials":242,"activeCount":55},[],{"trials":244,"activeCount":55},[],{"trials":246,"activeCount":55},[247],{"nctId":222,"briefTitle":223,"status":150,"phases":248,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":249,"interventions":250},[46],[230],[211,232],{"trials":252,"activeCount":55},[],{"trials":254,"activeCount":55},[],{"intervention":256,"totalTrials":22,"cells":257},"N-acetylcysteine",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":284,"PHASE4":286,"NA":288},{"trials":259,"activeCount":55},[],{"trials":261,"activeCount":55},[],{"trials":263,"activeCount":55},[264,273],{"nctId":265,"briefTitle":266,"status":150,"phases":267,"primaryCompletion":268,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":272},"NCT00568087","N-acetylcysteine in Alcohol Dependence",[44,45],"2009-08","2007-12",46,[26],[256],{"nctId":274,"briefTitle":275,"status":150,"phases":276,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT00211653","Acetylcysteine in the Prevention of Renal Failure After Bypass Surgery",[44,45],"2006-11","2003-04",102,[281],"Kidney Failure",[283],"N-Acetylcysteine",{"trials":285,"activeCount":55},[],{"trials":287,"activeCount":55},[],{"trials":289,"activeCount":55},[],{"intervention":291,"totalTrials":51,"cells":292},"Oxaliplatin and Docetaxel",{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":294,"activeCount":55},[],{"trials":296,"activeCount":55},[],{"trials":298,"activeCount":55},[299],{"nctId":300,"briefTitle":301,"status":174,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":309},"NCT00557206","Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer",[45],"2009-11","2005-04",35,[307,308],"Neoplasms","Head and Neck Neoplasms",[291],{"trials":311,"activeCount":55},[],{"trials":313,"activeCount":55},[],{"trials":315,"activeCount":55},[],{"intervention":317,"totalTrials":51,"cells":318},"ketamine-enhanced prolonged exposure",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":320,"activeCount":55},[],{"trials":322,"activeCount":55},[],{"trials":324,"activeCount":55},[325],{"nctId":326,"briefTitle":327,"status":150,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT03960658","Ketamine and Prolonged Exposure in PTSD",[44,45],"2019-11-18","2019-12-04","2019-04-03",12,[334],"Post-traumatic Stress Disorder",[317],{"trials":337,"activeCount":55},[],{"trials":339,"activeCount":55},[],{"trials":341,"activeCount":55},[],{"intervention":343,"totalTrials":51,"cells":344},"Modified-Release Prednisone",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":346,"activeCount":55},[],{"trials":348,"activeCount":55},[],{"trials":350,"activeCount":55},[351],{"nctId":352,"briefTitle":353,"status":150,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":362},"NCT02506192","Gulf War Illness Inflammation Reduction Trial",[45],"2023-10-19","2015-07",83,[359,16,360,361],"Chronic Inflammation","Fatigue","Cognitive Impairment",[343],{"trials":364,"activeCount":55},[],{"trials":366,"activeCount":55},[],{"trials":368,"activeCount":55},[],{"intervention":370,"totalTrials":51,"cells":371},"Botulinum Toxin Type A",{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":386,"PHASE4":388,"NA":390},{"trials":373,"activeCount":55},[],{"trials":375,"activeCount":55},[],{"trials":377,"activeCount":55},[378],{"nctId":379,"briefTitle":380,"status":199,"phases":381,"completion":201,"start":382,"enrollment":6,"conditions":383,"interventions":385},"NCT00211679","Intra-articularInjection of Botulinum Toxin Type",[45],"2004-06",[21,384],"Pain",[370],{"trials":387,"activeCount":55},[],{"trials":389,"activeCount":55},[],{"trials":391,"activeCount":55},[],{"intervention":393,"totalTrials":51,"cells":394},"Botulinum toxin A",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":396,"activeCount":55},[],{"trials":398,"activeCount":55},[],{"trials":400,"activeCount":55},[401],{"nctId":402,"briefTitle":403,"status":150,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT00403273","Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA)",[45],"2009-01","2006-07",54,[409],"Knee Pain",[393,411],"Normal Saline",{"trials":413,"activeCount":55},[],{"trials":415,"activeCount":55},[],{"trials":417,"activeCount":55},[],{"intervention":411,"totalTrials":51,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":421,"activeCount":55},[],{"trials":423,"activeCount":55},[],{"trials":425,"activeCount":55},[426],{"nctId":402,"briefTitle":403,"status":150,"phases":427,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":428,"interventions":429},[45],[409],[393,411],{"trials":431,"activeCount":55},[],{"trials":433,"activeCount":55},[],{"trials":435,"activeCount":55},[],{"intervention":437,"totalTrials":51,"cells":438},"Ketamine",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":461},{"trials":440,"activeCount":55},[],{"trials":442,"activeCount":55},[443],{"nctId":444,"briefTitle":445,"status":150,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":454},"NCT02577250","Ketamine Infusions for PTSD and Treatment-Resistant Depression",[44],"2016-06","2016-07","2015-05",20,[452,453],"Depressive Disorder, Treatment-Resistant","Stress Disorders, Post-Traumatic",[437],{"trials":456,"activeCount":55},[],{"trials":458,"activeCount":55},[],{"trials":460,"activeCount":55},[],{"trials":462,"activeCount":55},[],{"intervention":464,"totalTrials":51,"cells":465},"Ubiquinone",{"EARLY_PHASE1":466,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":467,"activeCount":55},[468],{"nctId":469,"briefTitle":470,"status":199,"phases":471,"primaryCompletion":472,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":477},"NCT03956017","Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery",[43],"2022-08-04","2013-08-05",341,[476],"Myocardial Injury",[464],{"trials":479,"activeCount":55},[],{"trials":481,"activeCount":55},[],{"trials":483,"activeCount":55},[],{"trials":485,"activeCount":55},[],{"trials":487,"activeCount":55},[]]